Widely utilized as first-line therapy for locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) [1], Crizotinib, known as one of the “legend drugs” due to its rapid development-to-market timeline, has demonstrated significant clinical efficacy and plays a pioneering role in the treatment of anti-NSCLC [2]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.